FDA grants Fast Track Designation to Sobi's pacritinib for VEXAS syndrome

The FDA has granted Fast Track Designation to Sobi's pacritinib for treating VEXAS syndrome, a rare autoinflammatory and hematologic disease with no approved therapy. This designation facilitates faster FDA interactions and rolling reviews, supporting Sobi's ongoing Phase II PAXIS trial expected to deliver topline data in 2027.

This Wire brief sits within Fusion42's coverage of Biotech.